Header Logo
Last Name


InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Methods for Monitoring of the Anti-Angiogenic Activity of Agents in Patients. 341-359.
    2. Melanoma biology. Community Oncology. 5:6-13.
    3. Erratum. American Journal of Clinical Oncology: Cancer Clinical Trials. 28:455.
    4. Erratum. Cancer Research. 61:5956.
    5. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma. ONCOLOGY (United States). 27.
    6. Ultrasound contrast microbubbles targeted to tumor angiogenesis specifically bind tumor-derived endothelial cells. Unknown Journal. 2:897-898.
    7. Investigating a new entubulation strategy to overcome peripheral nerve injury. 751-752.
    8. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 1-12.
    9. Review of US comparative economic evidence for treatment of metastatic renal cell carcinoma after failure of first-line VEGF inhibitor therapy. American Health and Drug Benefits. 6.
    10. The role of tissue culture in oncology research. Current Oncology. 5:67-69.
    11. The genetic study of cells. Current Oncology. 5:4-8.
    12. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy. Clinical Genitourinary Cancer.
    13. Implementation of an Interleukin-2 National Registry. Journal for ImmunoTherapy of Cancer. 2.
    14. Erratum. Cancer Research. 61:4297.
    Same Department Expand Description